Public Company Healthcare

Catalent Pharma Solutions

Somerset, New Jersey, United States

Global contract development and manufacturing organization (CDMO) providing development, manufacturing and delivery services for pharmaceutical, biotech and consumer health products.

Focus Areas
CDMO services, Drug development, Biologics manufacturing
Website
catalent.com

Tracked deals

4

4 tracked deals across 2019-2021.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Buyout

4 buyout

Catalent Pharma Solutions Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for Catalent Pharma Solutions. 1 2019 1 2020 2 2021

Supporting Data

Recent Transactions

  • Catalent Acquires Bettera Brands from Highlander Partners for $1 Billion
    August 30, 2021
    Buyer
    Catalent, Inc.
    Target
    Bettera Holdings, LLC (Bettera Brands)
    Seller
    Highlander Partners
    Industry
    Food & Beverage
    Location
    Texas, United States
    Type
    Buyout

    Catalent, Inc. agreed to acquire Bettera Holdings, LLC (Bettera Brands) from Highlander Partners for $1 billion. The acquisition expands Catalent's consumer health and nutraceutical manufacturing capabilities—adding Bettera's gummy, soft chew, and lozenge production capacity and approximately 500 employees across four U.S. facilities.

  • Catalent Acquires Delphi Genetics to Add Plasmid DNA Capabilities
    February 23, 2021
    Buyer
    Catalent, Inc.
    Target
    Delphi Genetics S.A.
    Industry
    Biotechnology
    Location
    Hainaut, Belgium
    Type
    Buyout

    Catalent has agreed to acquire 100% of Delphi Genetics, a Belgium-based plasmid DNA (pDNA) CDMO, and will integrate Delphi's pDNA development and cGMP manufacturing capabilities into its Cell & Gene Therapy business. The deal also supports Catalent's launch of pDNA services at its Rockville, Maryland facility, expanding integrated pDNA supply across Europe and the U.S.

  • Catalent Acquires MaSTherCell Global from Great Point Partners and Co-investors
    February 3, 2020
    Buyer
    Catalent Pharma Solutions, Inc.
    Target
    MaSTherCell Global
    Seller
    Great Point Partners, Orgenesis, SFPI-FPIM
    Industry
    Biotechnology
    Location
    Hainaut, Belgium
    Type
    Buyout

    Catalent Pharma Solutions has signed a definitive agreement to acquire MaSTherCell Global, a cell and gene therapy CDMO that Great Point Partners had invested in alongside Orgenesis and SFPI-FPIM. MaSTherCell, headquartered in Gosselies, Belgium with a U.S. facility in Houston, Texas, expands Catalent's cell and gene therapy development and manufacturing capabilities and adds significant European and U.S. capacity.

  • Catalent Acquires Paragon Bioservices for $1.2 Billion
    May 20, 2019
    Buyer
    Catalent, Inc.
    Target
    Paragon Bioservices, Inc.
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    Catalent, Inc. completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing partner for gene therapies, expanding Catalent’s biologics and gene therapy capabilities. Paragon’s Baltimore-area facilities and ~380 employees will join Catalent’s global biologics platform, while Catalent secured financing including incremental term loans and a convertible preferred issuance to Leonard Green & Partners to support the transaction.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 3 tracked deals by Catalent Pharma Solutions. Food & Beverage Buyers & Acquisitions 1 tracked deal by Catalent Pharma Solutions. Acquisitions in Maryland 1 tracked deal by Catalent Pharma Solutions. Acquisitions in Texas 1 tracked deal by Catalent Pharma Solutions.

Related articles

Selling a company? Get in front of buyers like Catalent Pharma Solutions

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →